PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2020; 03(02): 70-74
DOI: 10.4103/jdep.jdep_15_19
Original Article

Evaluation of Ischemia-Modified Albumin and Fibrinogen in Relation with High-Sensitive C-reactive Protein in Diabetic Foot Ulcers

Haleemath Afrah
0   A J Institute of Medical Sciences and Research Centre, Kuntikana, Mangalore, Karnataka, India
,
Reshma Sridhar
1   Department of Biochemistry, A J Institute of Medical Sciences and Research Centre, Kuntikana, Mangalore, Karnataka, India
,
Sushith Sushith
1   Department of Biochemistry, A J Institute of Medical Sciences and Research Centre, Kuntikana, Mangalore, Karnataka, India
,
Prathima Balakrishna
1   Department of Biochemistry, A J Institute of Medical Sciences and Research Centre, Kuntikana, Mangalore, Karnataka, India
,
M Hanumanthappa
2   Department of Surgery, Wayanad Institute of Medical Sciences, Meppadi, Kerala, India
,
Mukund Srinivasan
3   Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA
,
Madan Ramarajan
1   Department of Biochemistry, A J Institute of Medical Sciences and Research Centre, Kuntikana, Mangalore, Karnataka, India
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Context: Diabetic foot ulcer (DFU) is one of the most dreaded complication of diabetes which often affects the morbidity and mortality of a diabetic. Biomarkers are required for follow-up of these patients to prevent further complications to the affected limb. Aim: The aim of this study is to evaluate ischemia-modified albumin (IMA), fibrinogen in relation with high sensitive-C-reactive protein (hs-CRP) in patients with DFUs. Methods: a hospital-based cross-sectional study was carried out among 30 patients with DFU admitted in the surgery department of tertiary care teaching hospital. The duration of the study was 2 months. Serum IMA, hs-CRP, and plasma fibrinogen levels were measured. Results: The present study has demonstrated that IMA levels (P < 0.05) and fibrinogen levels (P < 0.05) are statistically significantly elevated in patients with DFU and had significant correlation with albumin and hs-CRP (P < 0.05). Conclusions: The use of IMA, hs-CRP, and fibrinogen may be incorporated during the follow-up of type 2 diabetes mellitus patients and may probably prevent the development of DFU and also possibly prevent lower limb amputation. Further studies with a larger number of patients with DFU are necessary to reach a definitive judgment.

Keywords

Diabetic foot - fibrinogen - high-sensitive C-reactive protein - ischemia-modified albumin


Publication History

Received: 09 October 2019

Accepted: 05 June 2020

Article published online:
16 June 2022

© 2020. Gulf Association of Endocrinology and Diabetes (GAED). All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006;69:331-5.
  • 2 Xu SM, Liang T. Clinical observation of the application of autologous peripheral blood stem cell transplantation for the treatment of diabetic foot gangrene. Exp Ther Med 2016;11:283-8.
  • 3 Martins-Mendes D, Monteiro-Soares M, Boyko EJ, Ribeiro M, Barata P, Lima J, et al. The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk. J Diabetes Complications 2014;28:632-8.
  • 4 American Diabetes Association. 1. Improving care and promoting health in populations: Standards of medical care in diabetes-2020. Diabetes Care 2020;43:S7-13.
  • 5 Erbersdobler HF, Faist V. Maillard reaction products: Uptake, metabolic transit and selected parameters of biopotency and safety. Forum Nutr 2003;56:353-5.
  • 6 Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001;15:44-54.
  • 7 Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus – Preliminary report. Dis Markers 2008;24:311-7.
  • 8 Muhtaroğlu S, Keti DB, Ünlühizarci K. Investigation of ischemia-modified albumin levels and some atherosclerosis-related serum parameters in patients with diabetic foot. Turk J Med Sci 2016;46:126-32.
  • 9 Ma SG, Jin Y, Bai F, Xu W, Yu W. Evaluation of ischemia modified albumin and c- reactive protein in type 2 diabetes with and without ketosis. Biomarker Insights 2012;7:19-26.
  • 10 Weigelt C, Rose B, Poschen U, Ziegler D, Friese G, Kempf K, et al. Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care 2009;32:1491-6.
  • 11 Taha A, Omar GA. Correlation of cathepsin D and hsCRP plasma levels with diabetic foot ulcer in Egyptian subjects: Control study. Imp J Interdiscip Res 2016;2:1371-6.
  • 12 Arık HO, Yalcin AD, Gumuslu S, Genç GE, Turan A, Sanlioglu AD. Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers. Med Sci Monit 2013;19:712-5.
  • 13 Li XH, Guan LY, Lin HY, Wang SH, Cao YQ, Jiang XY, et al. Fibrinogen: A marker in predicting diabetic foot ulcer severity. J Diabetes Res 2016;2016:2358321.
  • 14 Rattan R, Nayak D. High levels of plasma malondialdehyde, protein carbonyl, and fibrinogen have prognostic potential to predict poor outcomes in patients with diabetic foot wounds: A preliminary communication. Int J Low Extrem Wounds 2008;7:198-203.
  • 15 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-46.
  • 16 Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia – A preliminary report. J Emerg Med 2000;19:311-5.
  • 17 Koç F, Erdem S, Altunkaş F, Ozbek K, Gül EE, Kurban S, et al. Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study. Anadolu Kardiyol Derg 2011;11:582-7.
  • 18 Gui MH, Li X, Lu ZQ, Gao X. Fasting plasma glucose correlates with angiographic coronary artery disease prevalence and severity in Chinese patients without known diabetes. Acta Diabetol 2013;50:333-40.
  • 19 Jiao XM, Zhang XG, Xu XU, Yi C, Bin C, Cheng QP, et al. Blood glucose fluctuation aggravates lower extremity vascular disease in type 2 diabetes. Eur Rev Med Pharmacol Sci 2014;18:2025-30.
  • 20 Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: Evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26:1435-8.
  • 21 Ferreira AE, Freire AM, Voit EO. A quantitative model of the generation of N (epsilon)-(carboxymethyl) lysine in the Maillard reaction between collagen and glucose. Biochem J 2003;376:109-21.
  • 22 Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo) 2011;66:1677-80.
  • 23 Chawla R, Loomba R, Guru D, Loomba V. Ischemia modified albumin – A marker of glycemic control and vascular complications in type 2 diabetes mellitus. J Clin Diagn Res 2016;10:BC13-6.
  • 24 Refaat S, EL-Ghaffar NA, Khalil A. The relationship between ischemia modified albumin and lipids in type 2 Egyptian diabetic patients. Adv Biol Res 2014;8:18-22.
  • 25 Syvänen K, Korhonen P, Jaatinen P, Vahlberg T, Aarnio P. High-sensitivity C-reactive protein and ankle brachial index in a finnish cardiovascular risk population. Int J Angiol 2011;20:43-8.
  • 26 Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16 Suppl A: 11-4.
  • 27 Lewington SD, Thompson SG. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant metaanalysis. JAMA 2005;294:1799-809.
  • 28 Kunutsor SK, Kurl S, Zaccardi F, Laukkanen JA. Baseline and long-term fibrinogen levels and risk of sudden cardiac death: A new prospective study and meta-analysis. Atherosclerosis 2016;245:171-80.
  • 29 Papageorgiou N, Tousoulis D, Siasos G, Stefanadis C. Is fibrinogen a marker of inflammation in coronary artery disease? Hellenic J Cardiol 2010;51:1-9.